Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis

Journal of Controlled Release

Volumn 131, Issue 1, 2008, Pages 77-82

  Li, Feng ^a   Sun, Jian yong ^a   Wang, Ji yao ^a   Du, Shi lin ^a   Lu, Wei yue ^b   Liu, Min ^b   Xie, Chao ^b   Shi, Jian ying ^b  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Cyclic peptide; Hepatocyte growth factor; Liposomes; Liver cirrhosis; Therapeutic effect

Indexed keywords

AMINES; BIOACTIVITY; CELL DEATH; COLLAGEN; ETHYLENE; ETHYLENE GLYCOL; FIBER OPTICS; GLYCOLS; LIVER; PEPTIDES; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; SHAPE MEMORY EFFECT; SULFATE MINERALS; TURBULENT FLOW;

APOPTOSIS; ARG-GLY-ASP; COLLAGEN FIBERS; COLLAGEN SURFACE; CYCLIC PEPTIDE; HEPATOCYTE GROWTH FACTOR; IN VIVO DEGRADATION; IN-VIVO; LIVER CIRRHOSIS; MALEIMIDE; PHOSPHOETHANOLAMINE; POLYDISPERSITY INDEX; POSITIVE CELLS; PROCOLLAGEN; RAT LIVERS; STERICALLY STABILIZED LIPOSOMES; THERAPEUTIC EFFECT;

LIPOSOMES;

ARGINYLGLYCYLASPARTIC ACID; CHOLESTEROL; COLLAGEN; HYDROXYPROLINE; LIPOSOME; MACROGOL DERIVATIVE; MALEIMIDE[POLY(ETHYLENE GLYCOL)] 1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; MESSENGER RNA; METHOXYPOLYETHYLENE GLYCOL 2000 1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; N HYDROXYSULFOSUCCINIMIDE POLYOXYETHYLENE MALEIMIDE; PHOSPHATIDYLCHOLINE; PROCOLLAGEN; PROCOLLAGEN ALPHA1; RECOMBINANT SCATTER FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFICACY; ENCAPSULATION; HISTOLOGY; LIVER CIRRHOSIS; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; REMISSION; STEREOSPECIFICITY; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; COLLAGEN TYPE I; DRUG CARRIERS; HEPATOCYTE GROWTH FACTOR; HYDROXYPROLINE; LIPOSOMES; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALEIMIDES; OLIGOPEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; RATS;

EID: 52049106824     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.07.021     Document Type: Article

References (34)

1. Friedman S.L. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N. Engl. J. Med. 328 25 (1993) 1828-1835
2. Arai M., Niioka M., Maruyama K., Wada N., Fujimoto N., Nomiyama T., Tanaka S., and Okazaki I. Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon. Dig. Dis. Sci. 41 5 (1996) 995-1000
3. Beljaars L., Meijer D.K., and Poelstra K. Targeting hepatic stellate cells for cell-specific treatment of liver fibrosis. Front. Biosci. 1 7 (2002) e214-e222
4. Beljaars L., Molema G., Schuppan D., Greets A., De Bleser P.J., Weert B., Meijer D.K., and Poelstra K. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J. Biol. Chem. 275 17 (2000) 12743-12751
5. Du S.L., Pan H., Lu W.Y., Wang J., Wu J., and Wang J.Y. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J. Pharmacol. Exp. Ther. 322 2 (2007) 560-568
6. Nakamura T., Nawa K., and Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun. 122 3 (1984) 1450-1459
7. Russell W.E., McGowan J.A., and Bucher N.L. Partial characterization of a hepatocyte growth factor from rat platelets. J. Cell. Physiol. 119 2 (1984) 183-192
8. Luetteke N.C., and Michalopoulos G.K. Partial purification and characterization of a hepatocyte growth factor produced by rat hepatocellular carcinoma cells. Cancer. Res. 45 12 Pt 1 (1985) 6331-6337
9. Nakamura T., Teramoto H., and Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc. Natl. Acad. Sci. USA 83 17 (1986) 6489-6493
10. Nakamura T., Nawa K., Ichihara A., Kaise N., and Nishino T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS. Lett. 224 2 (1987) 311-316
11. Gohda E., Tsubouchi H., and Nakayama H. Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure. J. Clin. Invest. 81 2 (1988) 414-419
12. Funakoshi H., and Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. Clin. Chim. Acta. 327 1-2 (2003) 1-23
13. Matsuda Y., Matsumoto K., Ichida T., and Nakamura T. Hepatocyte growth factor suppresses the onset of liver cirrhosis and abrogates lethal hepatic dysfunction in rats. J. Biochem. 118 3 (1995) 643-649
14. Mizuno S., Matsumoto K., Li M.Y., and Nakamura T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB. J. 19 6 (2005) 580-582
15. 1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice. FASEB. J. 17 2 (2003) 268-270
16. Taniyama Y., Morishita R., Aoki M., Hiraoka K., Yamasaki K., Hashiya N., Matsumoto K., Nakamura T., Kaneda Y., and Ogihara T. Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy. Hypertension 40 1 (2002) 47-53
17. Kim W.H., Matsumoto K., Bessho K., and Nakamura T. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis. Am. J. Pathol. 166 4 (2005) 1017-1028
18. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., and Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta. 1237 2 (1995) 99-108
19. Wu J., Liu P., Zhu J.L., Maddukuri S., and Zern M.A. Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology 27 3 (1998) 772-778
20. Blume G., Cevc G., Crommelin M.D., Bakker-Woudenberg I.A., Kluft C., and Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim. Biophys. Acta. 1149 1 (1993) 180-184
21. Dubey P.K., Mishra V., Jain S., Mahor S., and Vyas S.P. Liposomes modified with cyclic RGD peptide for tumor targeting. J. Drug. Target. 12 5 (2004) 257-264
22. Ishak K., Baptista A., Bianchi L., Callea F., Groote J.D., and Gudat F. Histological grading and staging of chronic hepatitis. J. Hepatol. 22 6 (1995) 696-699
23. Kivirikko K.I., Laitinen O., and Prockop D.J. Modifications of a specific assay for hydroxyproline in urine. Anal. Biochem. 19 2 (1967) 249-255
24. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., Orlandi S., Pellicciari R., and Morelli A. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 5 (2004) 1497-1512
25. Sato M., Kakubari M., Kawamura M., Sugimoto J., Matsumoto K., and Ishii T. The decrease in total collagen fibers in the liver by hepatocyte growth factor after formation of cirrhosis induced by thioacetamide. Biochem. Pharmacol. 59 6 (2000) 681-690
26. Uematsu Y., Fujise N., Kohsaka K., Masunaga H., and Higashio K. Effective administration route for the deleted form of hepatocyte growth factor to exert its pharmacological effects. J. Pharm. Sci. 88 1 (1999) 131-135
27. Oe S., Fukunaka Y., Hirose T., Yamaoka Y., and Tabata Y. A trial on regeneration therapy of rat liver cirrhosis by controlled release of hepatocyte growth factor. J. Control. Release. 88 2 (2003) 193-200
28. Ueki T., Kaneda Y., Tsutsui H., Nakanishi K., Sawa Y., Morishita R., Matsumoto K., Nakamura T., Takahashi H., Okamoto E., and Fujimoto J. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 5 2 (1999) 226-230
29. Klibanov A.L., Maruyama K., Torchilin V.P., and Huang L. Amphipathic polyethyleneglycol effectively prolong the circulation time of liposomes. FEBS Lett. 268 1 (1990) 235-237
30. Cramer T., Schuppan D., Bauer M., Pfander D., Neuhaus P., and Herbst H. Hepatocyte growth factor and c-Met expression in rat and human liver fibrosis. Liver. Int. 24 4 (2004) 335-344
31. Lotersztajn S., Julien B., Teixeira-Clerc F., Grenard P., and Mallat A. Hepatic fibrosis: molecular mechanisms and drug targets. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 605-628
32. Wu J., and Zern M.A. Hepatic stellate cells: a target for the treatment of liver fibrosis. J. Gastroenterol. 35 9 (2000) 665-672
33. Aina O.H., Marik J., Liu R., Lau D.H., and Lam K.S. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol. Cancer Ther. 4 5 (2005) 806-813
34. Marcelino J., and McDevitt C.A. Attachment of articular cartilage chondrocytes to the tissue form of type VI collagen. Biochim. Biophys. Acta. 1249 2 (1995) 180-188